Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.26Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -2.50%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant scientific and regulatory progress, including positive EMA guidance and groundbreaking publications, which bolster the company's prospects. However, funding challenges and financial dependency on external sources pose risks to future clinical developments.Company Guidance
During the conference call on May 13, 2025, Acurx Pharmaceuticals provided guidance on several key metrics and future plans. The company reported a cash balance of $4.6 million as of March 31, 2025, compared to $3.7 million at the end of 2024, largely due to raising approximately $3.6 million through two registered direct offerings. Research and development expenses decreased to $0.6 million for the first quarter of 2025 from $1.6 million in the previous year, primarily due to decreased manufacturing and consulting costs. General and administrative expenses also dropped to $1.6 million from $2.8 million, attributed to reduced professional fees and share-based compensation costs. The company reported a net loss of $2.1 million, or $0.11 per diluted share, down from a net loss of $4.4 million, or $0.28 per diluted share, in the same period the previous year. Looking ahead, Acurx plans to continue exploring funding opportunities for its Phase 3 ibezapolstat clinical trial program and expects to maintain reduced operating expenses until the trial commences.Successful Direct Offerings
The company closed a $2.5 million registered direct offering in January and a $1.1 million registered direct offering in March, providing crucial funds for operations.
Positive Regulatory Guidance
Received positive regulatory guidance from the European Medicines Agency for the ibezapolstat Phase 3 clinical trial program, aligning with the FDA on key aspects.
Scientific Advancements
New publications in the Journal of Antimicrobial Agents and Chemotherapeutics highlighted the microbiome restorative potential of ibezapolstat and its selective antibacterial activity.
Patent Milestones
Secured new patents in Japan and India for DNA pol IIIC inhibitors, expiring in 2039, strengthening the ACX-375 pre-clinical antibiotic program.
Significant Reduction in Net Loss
Net loss decreased to $2.1 million from $4.4 million year-over-year, showing improved financial management despite ongoing R&D expenditures.
Publication Acceptance
Phase 2 clinical trial data accepted for publication in Lancet Microbe, showcasing ibezapolstat's high clinical cure rates and safety profile.
ACXP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ACXP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $0.40 | $0.38 | -5.00% |
Mar 18, 2025 | $0.47 | $0.40 | -14.89% |
Nov 13, 2024 | $1.85 | $1.82 | -1.62% |
Aug 09, 2024 | $1.90 | $1.88 | -1.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Acurx Pharmaceuticals (ACXP) report earnings?
Acurx Pharmaceuticals (ACXP) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is Acurx Pharmaceuticals (ACXP) earnings time?
Acurx Pharmaceuticals (ACXP) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ACXP EPS forecast?
ACXP EPS forecast for the fiscal quarter 2025 (Q2) is -0.12.